Interferon beta versus glatiramer acetate for relapsing-remitting multiple sclerosis (Q24194800)

9

0 references

Bianca Weinstock-Guttman

object named as

Bianca Weinstock-Guttman

10

0 references

author name string

Alberto Vaona

2

0 references

Marco Rovaris

3

0 references

Francesco Berardo

4

0 references

Serena Frau

5

0 references

Anna Gandini

6

0 references

Anna Longobardi

7

0 references

Giulio Rigon

Cochrane Database of Systematic Reviews

8

0 references

publication date

26 July 2014

0 references

published in

0 references

cites work

Efficacy of treatment of MS with IFNbeta-1b or glatiramer acetate by monthly brain MRI in the BECOME study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009333.PUB2

Randomized study combining interferon and glatiramer acetate in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009333.PUB2

Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009333.PUB2

250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009333.PUB2

Therapeutic outcome 3 years after switching of immunomodulatory therapies in patients with relapsing-remitting multiple sclerosis in Argentina

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009333.PUB2

Glatiramer acetate: a review of its use in relapsing-remitting multiple sclerosis and in delaying the onset of clinically definite multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009333.PUB2

Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009333.PUB2

Phase III dose-comparison study of glatiramer acetate for multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009333.PUB2

Disease-modifying drugs in childhood-juvenile multiple sclerosis: results of an Italian co-operative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009333.PUB2

Effect of disease-modifying therapies on brain volume in relapsing-remitting multiple sclerosis: results of a five-year brain MRI study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009333.PUB2

Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009333.PUB2

A randomized controlled double-masked trial of albuterol add-on therapy in patients with multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009333.PUB2

[Immunomodulatory treatments for multiple sclerosis: lessons from direct comparative studies].

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009333.PUB2

Temporal trends in the incidence of multiple sclerosis: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009333.PUB2

New acute and chronic black holes in patients with multiple sclerosis randomised to interferon beta-1b or glatiramer acetate

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009333.PUB2

Impact of inflammation on brain volume in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009333.PUB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009333.PUB2

Meta-analysis in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009333.PUB2

Interferon-beta mechanisms of action in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009333.PUB2

Interferon β-1b and glatiramer acetate effects on permanent black hole evolution

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009333.PUB2

Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009333.PUB2

Neutralizing antibodies to interferon beta-1b multiple sclerosis: a clinico-radiographic paradox in the BEYOND trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009333.PUB2

Grading quality of evidence and strength of recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009333.PUB2

A network meta-analysis of randomized controlled trials for comparing the effectiveness and safety profile of treatments with marketing authorization for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009333.PUB2

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009333.PUB2

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009333.PUB2

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009333.PUB2

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009333.PUB2

The CombiRx trial of combined therapy with interferon and glatiramer acetate in relapsing remitting MS: Design and baseline characteristics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009333.PUB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009333.PUB2

Treatment patterns in multiple sclerosis: administrative claims analysis over 10 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009333.PUB2

Assessing risks of multiple sclerosis therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009333.PUB2

Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009333.PUB2

Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009333.PUB2

Brain atrophy and lesion load predict long term disability in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009333.PUB2

New diagnostic criteria for multiple sclerosis: guidelines for research protocols

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009333.PUB2

The mechanism of action of glatiramer acetate treatment in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009333.PUB2

Interferon in relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009333.PUB2

Do interferon beta-1b and glatiramer acetate grow brain?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009333.PUB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009333.PUB2

The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009333.PUB2

Beta blockade during and after myocardial infarction: an overview of the randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009333.PUB2

Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009333.PUB2

European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009333.PUB2

Efficacy and safety of interferon beta-1b sc in older RRMS patients—a posthoc analysis of the BEYOND study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009333.PUB2

Gray matter atrophy is related to long-term disability in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009333.PUB2

7 January 2021

Treatments for relapsing-remitting multiple sclerosis: summarising current information by network meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009333.PUB2

7 January 2021

REGARD: what can we learn from randomised, open-label, head-to-head studies?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009333.PUB2

7 January 2021

Increasing use of disease modifying drugs for MS in Canada.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009333.PUB2

7 January 2021

MRI only conversion to multiple sclerosis following a clinically isolated syndrome.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009333.PUB2

7 January 2021

Effect of disease-modifying drugs on cortical lesions and atrophy in relapsing-remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009333.PUB2

7 January 2021

Clinical consequences of MRI activity in treated multiple sclerosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009333.PUB2

7 January 2021

In the coming year we should abandon interferons and glatiramer acetate as first line therapy for MS: no

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009333.PUB2

7 January 2021

In the coming year we should abandon interferons and glatiramer acetate as first line therapy for MS: Commentary

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009333.PUB2

7 January 2021

Interferon-beta treatment for relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009333.PUB2

7 January 2021

10.1002/14651858.CD009333.PUB2

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

1 reference

Consolidated OpenCitations Corpus – April 2017

PubMed publication ID

25062935

1 reference

Consolidated OpenCitations Corpus – April 2017